R - Profile

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

US Patents for r

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Regeneron Pharmaceuticals	LIBTAYO	cemiplimab-rwlc	INJECTABLE;INTRAVENOUS	761097	001	2019-03-20				RX
Regeneron Pharmaceuticals	DUPIXENT	dupilumab	INJECTABLE; INJECTION	761055	001	2017-03-28	9,763,918	Knopp Biosciences LLC (Pittsburgh, PA)	2033-08-13	RX		search
Regeneron Pharmaceuticals	DUPIXENT	dupilumab	INJECTABLE; INJECTION	761055	001	2017-03-28	9,290,574	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)	2033-07-11	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.